Every 8-K that Aimei Health Technology Co., Ltd Unit (AFJKU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AFJKU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AFJKU filings page.
Aimei Health Technology Co., Ltd. (AFJK) extended the deadline to complete its initial business combination by one month, making a payment of $34,330.96 into its trust account to move the Termination Date from September 6, 2026 to October 6, 2026. This amount represents the lesser of $80,000 for all outstanding public shares and $0.033 per outstanding public share for the monthly extension and is the 22nd extension permitted under its Amended and Restated Articles of Association.
To fund the extension payment, the company issued an unsecured Promissory Note for $34,330.96 to Aimei Investment Ltd. The note bears no interest and becomes due upon consummation of the planned business combination with United Hydrogen. The payee may convert the note into private units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one-fifth of one ordinary share, immediately prior to closing by giving two business days’ written notice.
Aimei Health Technology Co., Ltd. (AFJK) reports that Nasdaq has notified it that its Market Value of Listed Securities (MVLS) has been below $50,000,000 and its Market Value of Publicly Held Shares (MVPHS) has been below $15,000,000 for the last 30 consecutive business days, violating Nasdaq Global Market continued listing standards.
The company has two separate 180-day compliance periods, through February 17, 2027, to have MVLS at or above $50,000,000 and MVPHS at or above $15,000,000 for at least 10 consecutive business days. AFJK’s shares continue to trade on the Nasdaq Global Market, but failure to regain compliance could lead to delisting or a transfer to the Nasdaq Capital Market.
Aimei Health Technology Co., Ltd deposited $34,330.96 into its trust account for public shareholders, equal to the lesser of $80,000 in total or $0.033 per outstanding public share for a monthly extension. This extends the deadline to consummate its initial business combination from August 6, 2026 to September 6, 2026, representing the company’s 21st permitted extension.
To fund this payment, Aimei Health issued an unsecured, non‑interest‑bearing promissory note for $34,330.96 to Aimei Health Ltd, due upon completion of its business combination with United Hydrogen. The payee may convert the note into private units at $10.00 per unit, each unit including one ordinary share and a right to receive one‑fifth of an ordinary share, by giving written notice at least two business days before closing.
Aimei Health Technology Co., Ltd. has terminated its planned business combination with United Hydrogen Group Inc. and related Cayman entities. The company sent a termination notice on July 7, 2026 under Section 9.1(b) of the Business Combination Agreement after the deal failed to close by the applicable outside date.
As a result, the Business Combination Agreement, originally signed on June 19, 2024 and amended on June 6, 2025, is no longer in effect and the proposed transaction will not be consummated. Aimei’s CEO stated the company remains confident in finding a compelling future transaction.
Aimei Health Technology Co., Ltd extended the deadline to complete its initial business combination by one month, moving the termination date from July 6, 2026 to August 6, 2026. To do this, the company deposited $34,330.96 into its trust account for public shareholders.
The deposit equals the lesser of $80,000 for all outstanding public shares or $0.033 per public share for the month and represents the twentieth permitted extension. This amount is funded by an unsecured, non‑interest‑bearing promissory note to Aimei Health Ltd, which may be converted into private units at $10.00 per unit immediately before closing the planned business combination with United Hydrogen.
Aimei Health Technology Co., Ltd. reports a board change. On June 24, 2026, director Julianne Huh resigned for personal reasons, with no disagreement on the company’s operations, policies, or practices. She confirmed all compensation has been paid and released the company from any related claims.
On June 29, 2026, the board appointed Daniel Veikko Polvi as a new director. He holds an MBA from Norwegian Business School and has served since May 2019 as managing director of Shearwater Limited, providing business management and strategic consulting services to international corporations. The company states there are no family relationships or related-party transactions requiring disclosure.
Aimei Health Technology Co., Ltd deposited an Extension Payment of $34,330.96 into its trust account to extend the deadline to complete its initial business combination by one month, moving the Termination Date from June 6, 2026 to July 6, 2026.
To fund this nineteenth extension, the company issued an unsecured promissory note dated June 4, 2026 to its sponsor Aimei Health Ltd and United Hydrogen Group Inc., with each contributing $17,165.48. The note bears no interest and is due upon completion of the planned business combination with United Hydrogen, and the payees may optionally convert the principal into private units at $10.00 per unit immediately before closing.
Aimei Health Technology Co., Ltd received a Nasdaq deficiency notice on May 19, 2026 because it did not file its Form 10-Q for the quarter ended March 31, 2026, which was due May 15, 2026. This means the company is currently out of compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic SEC reports.
The notice does not immediately affect the listing or trading of Aimei’s ordinary shares, rights, or units on Nasdaq. The company has 60 calendar days from the notice date to either file the missing quarterly report or submit a compliance plan, and could receive up to 180 calendar days from the report’s due date if Nasdaq accepts its plan. Aimei states it is working diligently to complete the filing and expects to regain compliance.
Aimei Health Technology Co., Ltd extended the deadline to complete its initial business combination by one month, moving the termination date from May 6, 2026 to June 6, 2026. To fund this extension, the company deposited an Extension Payment of $34,330.96 into its trust account for public shareholders.
In connection with this move, Aimei Health issued a zero‑interest Promissory Note for $34,330.96 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., with each contributing $17,165.48. The note is due upon completion of the business combination with United Hydrogen and can be converted into private units at $10.00 per unit immediately before closing.
Aimei Health Technology Co., Ltd reported that Nasdaq notified the company on April 17, 2026 that it is out of compliance with Nasdaq Listing Rule 5250(c)(1) because it has not filed its Form 10-K for the year ended December 31, 2025. The report was due March 31, 2026, and a Form 12b-25 was filed on April 1, 2026. The notice does not immediately affect trading of Aimei’s ordinary shares, rights, or units on Nasdaq, but continued noncompliance could result in delisting.
The company has 60 days from the notice date to either file the annual report or submit a compliance plan, and may receive up to 180 days from the original due date if a plan is accepted. Aimei states it is working diligently to complete and file the Form 10-K and expects to regain compliance.
Aimei Health Technology Co., Ltd extended the deadline to complete its initial business combination with United Hydrogen Group Inc. by one month, moving the termination date from March 6, 2026 to April 6, 2026. To fund this sixteenth extension, a total of $34,330.96 was deposited into the company’s trust account for public shareholders, calculated as the lesser of $80,000 for all outstanding public shares or $0.033 per outstanding public share for the month.
In connection with the extension, the company issued an unsecured promissory note for $34,330.96 on March 4, 2026 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., with each contributing $17,165.48. The note bears no interest and becomes due when the business combination with United Hydrogen is completed. The payees may convert the note into private units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one-fifth of one ordinary share, if they notify the company at least two business days before the business combination closes.
Aimei Health Technology Co., Ltd has extended the deadline to complete its initial business combination by one month, moving the termination date from February 6, 2026 to March 6, 2026. To fund this fifteenth monthly extension, an aggregate $34,330.96 was deposited into the company’s trust account for public shareholders.
In connection with this extension, the company issued an unsecured promissory note for $34,330.96 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., each contributing $17,165.48. The note bears no interest and becomes payable when the company consummates its proposed business combination with United Hydrogen. The payees may instead convert the note into private units of Aimei Health at $10.00 per unit immediately before closing, with each unit consisting of one ordinary share and a right to receive one-fifth of one ordinary share.
Aimei Health Technology Co., Ltd deposited $150,000 into its trust account to extend the deadline to complete its initial business combination by one month, moving the termination date from September 6, 2025 to October 6, 2025. This is the tenth of up to 12 one‑month extensions allowed under its current Articles of Association.
To fund this extension, the company issued a $150,000 unsecured promissory note on September 5, 2025 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., with each contributing $75,000. The note bears no interest and becomes due when the company completes a business combination with United Hydrogen. The payees may instead convert the note into private units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one‑fifth of one ordinary share, immediately before the business combination closes.